Oestrogens in fetal and maternal fluids throughout pregnancy in the pig and comparisons with the ewe and cow

1985 ◽  
Vol 106 (3) ◽  
pp. 355-360 ◽  
Author(s):  
H. A. Robertson ◽  
R. J. Dwyer ◽  
G. J. King
Keyword(s):  
Early Pregnancy ◽  
Allantoic Fluid ◽  
Maternal Blood ◽  
Maternal Plasma ◽  
Maternal Urine ◽  
Oestrone Sulphate ◽  
Fetal Fluids

ABSTRACT In order to correlate the concentrations of oestrogens in the fetal fluids of the pig with those observed in the maternal blood and urine, changes in the concentrations of oestrone, oestradiol-17β, oestrone sulphate, oestradiol sulphates and oestrone glucuronide were assessed throughout pregnancy in the fetal and maternal fluids. In general, the pattern of change was similar for all oestrogens measured in both fetal and maternal fluids. Since the concentration of oestrogens in allantoic fluid during early pregnancy is reflected in the concentration of these steroids in maternal plasma and excreted in the maternal urine, the rise and fall of oestrogen concentrations around day 30 is suggestive of synthesis followed by a virtual cessation of oestrogen production until the fetus or placenta again produce increasing amounts detectable after day 45. These findings contrast sharply with those in the cow and the ewe where, although similar peaks in oestrogen concentrations are observable in allantoic fluid during early pregnancy, they are not reflected in blood. J. Endocr. (1985) 106, 355–360

Patterns of conceptus development and of progesterone concentrations in maternal blood preceding spontaneous early pregnancy failure in mares

2018 ◽  
Vol 30 (8) ◽  
pp. 1066 ◽  
Author(s):  
Keith J. Betteridge ◽  
James I. Raeside ◽  
Rudolf O. Waelchli ◽  
Heather L. Christie ◽  
M. Anthony Hayes
Keyword(s):  
Early Pregnancy ◽  
Experimental Studies ◽  
Maternal Blood ◽  
Maternal Plasma ◽  
Plasma Progesterone ◽  
Pregnancy Failure ◽  
Early Pregnancy Failure ◽  
Conceptus Development ◽  
Simultaneous Loss

Sixteen cases of spontaneous pregnancy loss (11 of singletons and five of pairs of twins) are described. The losses occurred between gestation Days 13 and 25 in 12 mares being monitored almost daily by transrectal ultrasonography (for measurement of conceptus growth) and blood sampling (for determination of maternal plasma progesterone concentrations as evidence of luteolysis) in experimental studies of early pregnancy. In 10 of the 16 cases the uterus was flushed and eight conceptuses were recovered for morphological assessment. Five of the 11 losses of singletons occurred before Day 16 and, with one exception, were preceded or accompanied by luteolysis. The remaining six singleton pregnancies failed after Day 16, with two cases evidencing luteolysis beforehand. Thus, overall, 6/11 singleton losses were associated with luteolysis while 5/11 were not. The five cases of simultaneous loss or degeneration of twin conceptuses all occurred on Day 19 or 20, preceded by luteolysis in only one case. These observations suggest that while the causes of spontaneous early pregnancy failure are multifactorial, luteolysis might contribute to the problem more often than has been previously contended.

METABOLISM OF DEHYDROEPIANDROSTERONE SULPHATE AND OESTRONE SULPHATE FOLLOWING IN SITU PLACENTAL PERFUSION AT MIDPREGNANCY

1971 ◽  
Vol 66 (4) ◽  
pp. 637-647 ◽  
Author(s):  
J. Schwers ◽  
T. Vancrombreucq ◽  
M. Govaerts ◽  
G. Eriksson ◽  
E. Diczfalusy
Keyword(s):  
Radioactive Material ◽  
Dehydroepiandrosterone Sulphate ◽  
Placental Perfusion ◽  
Carbon 14 ◽  
Maternal Urine ◽  
Oestrone Sulphate ◽  
Unchanged Form ◽  
Urine Specimens

ABSTRACT Two midgestation placentas were perfused in situ with a combination of [7α-3H] dehydroepiandrosterone sulphate and [4-14C] oestrone sulphate and metabolites were isolated from the placentas, perfusates and maternal urine specimens. Approximately 70 per cent of the perfused radioactive material was recovered from these three sources. The bulk of the administered radioactive material was recovered in an unchanged form from the perfusates; some 2–4 per cent was excreted in the urine and less than 0.5% was found in the placentas. The tritium to carbon-14 ratio of the unconjugated material isolated from the perfusates and placentas was higher, and that of the conjugated material recovered from the same sources was lower than the ratio of the administered material. In addition, more tritium than carbon-14 labelled material was present in the urine. Approximately 2 per cent of the perfused dehydroepiandrosterone sulphate was recovered in the form of phenolic steroids, mostly from the urine. From this source double labelled oestrone, oestriol, 16α-hydroxy-oestrone and 16-epioestriol were isolated. The tritium to carbon-14 ratio of all oestrogens isolated from the urine was higher than that of the perfused material. From the urine specimens 10 to 15 times more double labelled oestriol than oestrone was isolated.

scholarly journals Objective assessment of alcohol consumption in early pregnancy using phosphatidylethanol: a cross‐sectional study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Leonieke J. Breunis ◽  
Sophie Wassenaar ◽  
Barbara J. Sibbles ◽  
Ab A. Aaldriks ◽  
Hilmar H. Bijma ◽  
...  
Keyword(s):  
Alcohol Consumption ◽  
Early Pregnancy ◽  
Gestational Age ◽  
Care Provider ◽  
Objective Assessment ◽  
Obstetric Care ◽  
Tertiary Hospital ◽  
Maternal Blood ◽  
Added Value ◽  
Cross Sectional

Abstract Background Alcohol consumption during pregnancy is associated with major birth defects and developmental disabilities. Questionnaires concerning alcohol consumption during pregnancy underestimate alcohol use while the use of a reliable and objective biomarker for alcohol consumption enables more accurate screening. Phosphatidylethanol can detect low levels of alcohol consumption in the previous two weeks. In this study we aimed to biochemically assess the prevalence of alcohol consumption during early pregnancy using phosphatidylethanol in blood and compare this with self-reported alcohol consumption. Methods To evaluate biochemically assessed prevalence of alcohol consumption during early pregnancy using phosphatidylethanol levels, we conducted a prospective, cross-sectional, single center study in the largest tertiary hospital of the Netherlands. All adult pregnant women who were under the care of the obstetric department of the Erasmus MC and who underwent routine blood testing at a gestational age of less than 15 weeks were eligible. No specified informed consent was needed. Results The study was conducted between September 2016 and October 2017. In total, we received 1,002 residual samples of 992 women. After applying in- and exclusion criteria we analyzed 684 samples. Mean gestational age of all included women was 10.3 weeks (SD 1.9). Of these women, 36 (5.3 %) tested positive for phosphatidylethanol, indicating alcohol consumption in the previous two weeks. Of women with a positive phosphatidylethanol test, 89 % (n = 32) did not express alcohol consumption to their obstetric care provider. Conclusions One in nineteen women consumed alcohol during early pregnancy with a high percentage not reporting this use to their obstetric care provider. Questioning alcohol consumption by an obstetric care provider did not successfully identify (hazardous) alcohol consumption. Routine screening with phosphatidylethanol in maternal blood can be of added value to identify women who consume alcohol during pregnancy.

Phenoxybenzameve Placental Transfer during the Third Trimester

1996 ◽  
Vol 30 (11) ◽  
pp. 1249-1251 ◽  
Author(s):  
Maria L Santeiro ◽  
Carine Stromquist ◽  
Lance Wyble
Keyword(s):  
Amniotic Fluid ◽  
Perinatal Depression ◽  
Placental Transfer ◽  
Male Infant ◽  
Maternal Blood ◽  
Maternal Plasma ◽  
Third Trimester ◽  
Days Of Therapy ◽  
Maternal Hypertension ◽  
Placental Passage

OBJECTIVE: To report phenoxybenzamine placental transfer in the treatment of maternal hypertension secondary to pheochromocytoma. CASE SUMMARY: A 22-year-old woman diagnosed with pheochromocytoma was medically managed at 33 weeks gestation with oral phenoxybenzamine and labetalol until delivery 26 days later. To determine phenoxybenzamine placental passage, at the time of cesarean section simultaneous samples were obtained from the cord blood, maternal blood, and amniotic fluid. Additional blood samples were obtained from the newborn at 32 and 80 hours of life. Mean concentrations of phenoxybenzamine from cord and maternal plasma and in amniotic fluid were 103.3,66, and 79.3 ng/mL, respectively; the newborn's plasma concentration at 32 hours of life was 22.3 ng/mL. At the time of delivery, the 2475-g male infant exhibited perinatal depression; mild transient hypotension was also noted for the first few days of life. DISCUSSION: The fetal—maternal plasma accumulation ratio of 1.6:1 indicates that at this gestational age after 26 days of therapy, the placental transfer of phenoxybenzamine occurs and is accompanied by accumulation in the fetal blood. CONCLUSIONS: Because of the placental transfer of phenoxybenzamine, mild perinatal depression and transient hypotension may occur in newborns of mothers receiving this medication. These newborns must be closely monitored during the first few days of life for respiratory depression and hypotension.

Maternal Thyroid Function, Use of Antithyroid Drugs in Early Pregnancy, and Birth Defects

2019 ◽  
Vol 104 (12) ◽  
pp. 6040-6048 ◽  
Author(s):  
Stine Linding Andersen ◽  
Louise Knøsgaard ◽  
Jørn Olsen ◽  
Peter Vestergaard ◽  
Stig Andersen
Keyword(s):  
Thyroid Function ◽  
Birth Defects ◽  
Early Pregnancy ◽  
Antithyroid Drug ◽  
Maternal Blood ◽  
Antithyroid Drugs ◽  
Birth Cohorts ◽  
Increased Risk ◽  
Maternal Thyroid

Abstract Context Antithyroid drug (ATD) therapy in early pregnancy is associated with birth defects, but more data are needed to substantiate the risk associated with different types of ATD. Furthermore, the role of abnormal maternal thyroid function per se remains unclarified. Objective To evaluate the risk of birth defects associated with the use of ATD in an extended nationwide cohort and the role of abnormal maternal thyroid function in birth cohorts including stored maternal blood samples from early pregnancy. Participants Danish pregnant women and their live-born children, including 1,243,353 children from a Nationwide Register-Based Cohort (NRBC), 1997 to 2016; 8830 children from the Danish National Birth Cohort (DNBC), 1997 to 2003; and 14,483 children from the North Denmark Region Pregnancy Cohort (NDRPC), 2011 to 2015. Main Outcome Measures Birth defects diagnosed before 2 years of age. Results In the NRBC, altogether 2718 (0.2%) children had been exposed to ATD in early pregnancy. The overall frequency of birth defects was 6.7% (95% CI, 6.7% to 6.8%) in nonexposed children and higher after exposure to methimazole/carbimazole (9.6%; 95% CI, 8.2% to 11.2%) and propylthiouracil (8.3%; 95% CI, 6.7% to 10.3%). On the other hand, the frequency of maternal thyroid dysfunction in early pregnancy was similar in the random cohort and in cases of birth defect in the DNBC (12.4 vs 12.6%, P = 0.8) and the NDRPC (15.1 vs 15.4%, P = 0.8). Conclusions Results corroborate an increased risk of birth defects associated with the use of ATD in early pregnancy and suggest that abnormal maternal thyroid function is not a major risk factor for birth defects.

scholarly journals Variations in Infant CYP2B6 Genotype Associated with the Need for Pharmacological Treatment for Neonatal Abstinence Syndrome in Infants of Methadone-Maintained Opioid-Dependent Mothers

2017 ◽  
Vol 34 (09) ◽  
pp. 918-921 ◽  
Author(s):  
Poppy McLaughlin ◽  
Cheryl Gillis ◽  
Michael Osselton ◽  
Helen Mactier
Keyword(s):  
Pharmacological Treatment ◽  
Maternal Blood ◽  
Maternal Plasma ◽  
Genomic Variation ◽  
Neonatal Abstinence Syndrome ◽  
Abstinence Syndrome ◽  
Buccal Swabs ◽  
Cyp2b6 Gene ◽  
Observational Cohort

Background Neonatal abstinence syndrome (NAS) in infants of methadone-maintained opioid-dependent (MMOD) mothers cannot be predicted in individual cases. We investigated whether variation in infant genotype is associated with severity of NAS. Methods This is a pilot observational cohort study of 21 MMOD mothers and their newborns. Infant buccal swabs were obtained soon after delivery, together with a maternal blood sample for the determination of maternal plasma methadone concentration. Genomic variation in five opioid-related genes (ABCB1, COMT, CYP2B6, CYP2D6, and OPRM1) was ascertained from infant buccal swabs and related to need for pharmacological treatment of NAS. Results Out of 21 infants, 11 (52%) required treatment for NAS. Mothers of treated infants tended to have been prescribed higher doses of methadone, but plasma methadone concentrations did not differ between mothers of treated or untreated babies. Treated and untreated babies did not differ in terms of method of feeding. Treated infants were more likely to carry the normal (homozygous) allele at 516 and 785 regions of CYP2B6 gene (p = 0.015 and 0.023, respectively). There were no differences in any other genes between infants who did or did not require treatment for NAS. Conclusion Genomic variation in CYP2B6 may explain, at least in part, severity of NAS.

Atrial natriuretic factor in maternal and fetal sheep

1987 ◽  
Vol 252 (2) ◽  
pp. E279-E282 ◽  
Author(s):  
C. Y. Cheung ◽  
D. M. Gibbs ◽  
R. A. Brace
Keyword(s):  
Atrial Natriuretic Factor ◽  
Allantoic Fluid ◽  
Maternal Plasma ◽  
Fetal Kidney ◽  
Fetal Sheep ◽  
Fetal Plasma ◽  
Natriuretic Factor ◽  
Pregnant Sheep ◽  
Fetal Urine ◽  
Atrial Natriuretic

To determine atrial natriuretic factor (ANF) concentrations in the circulation and body fluids of adult pregnant sheep and their fetuses, pregnant ewes were anesthetized with pentobarbital sodium, and the fetuses were exteriorized for sampling. ANF concentration, as measured by radioimmunoassay, was 47 +/- 6 (SE) pg/ml in maternal plasma, which was significantly higher than the 15 +/- 3 pg/ml in maternal urine. In the fetus, plasma ANF concentration was 265 +/- 49 pg/ml, 5.6 times that in maternal plasma. No umbilical arterial and venous difference in ANF concentration was observed. Fetal urine ANF concentration (13 +/- 2 pg/ml) was significantly lower than that in fetal plasma, and was similar to that measured in amniotic and allantoic fluid. In chronically catheterized maternal and fetal sheep, fetal plasma ANF was again 5.1 times that in maternal plasma, and these levels were not different from those measured in acutely anesthetized animals. These results demonstrate that immunoreactive ANF is present in the fetal circulation at levels higher than those found in the mother. The low concentration of ANF in fetal urine suggests that ANF is probably metabolized and/or reabsorbed by the fetal kidney.

Sign in / Sign up

Export Citation Format

Share Document